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The associations of depression and hypertension with 
brain volumes: independent or interactive?
Maaike Meurs, Nynke A Groenewold, Annelieke M Roest, 
Nic JA van der Wee, Dick J Veltman, 
Marie-José van Tol,  Peter de Jonge




Independent studies on major depressive disorder (MDD) and hypertension, 
suggest overlapping abnormalities in brain regions associated with emotional 
and autonomic processing. However, the unique and interactive effects of MDD 
and hypertension have never been studied in a single sample. Brain volume in 
these areas may be an explanatory link in the comorbidity between MDD and 
hypertension. Voxel-based morphometry was used to test for main effects of MDD 
(N=152) and hypertension (N=82) and their interactions on gray and white matter 
volumes. Voxel-wise results are reported at p<.05 FWE corrected for the spatial 
extent of the whole brain and a priori regions of interest (ROIs: hippocampus, 
anterior cingulate cortex (ACC) and inferior frontal gyrus (IFG)). In addition, 
analyses on the extracted total volumes of our ROIs were performed. Interactive 
effects in the mid cingulate cortex (MCC) (pFWE=.01), cerebellum (pFWE=.01) 
and in the ACC total ROI volume (p=.02) were found. MDD in the presence, 
but not in the absence of hypertension was associated with lower volumes in 
the ACC and MCC, and with a trend towards larger gray matter volume in the 
cerebellum. No associations with white matter volumes were observed. Results 
suggest that the combination of MDD and hypertension has a unique effect on 
brain volumes in areas implicated in the regulation of emotional and autonomic 
functions. Brain volume in these regulatory areas may be an explanatory link in 
the comorbidity between hypertension and MDD.




The incidence of hypertension is increased in depressed patients compared to 
the general population.1 Moreover, both hypertension and depression increase 
the risk of incident cardiovascular disease (CVD) and accelerate the progression 
of CVD.2,3 Multiple biological factors have been proposed to play a role in 
the association between depression and vascular related diseases,4 including 
inflammation, hypothalamus-pituitary-adrenal (HPA) axis dysregulation, and 
autonomic dysfunction, reflected by decreased heart rate variability. Although 
both depression and hypertension have independently been associated with 
abnormalities in brain structure and function, regional brain morphology as a 
shared biological link has rarely been studied. 
Depression has been associated with gray matter (GM) volume loss 
predominantly in prefrontal-limbic networks, such as the anterior cingulate 
cortex (ACC), hippocampus, and inferior frontal gyrus (IFG),5-8 which have 
been implicated in processing of emotional information.9 It is not fully clear 
whether alterations in regional brain volumes are a cause or consequence of 
depression, or both. Conceivably, pre-existing abnormalities in brain regions 
involved in emotion processing may render individuals vulnerable to depression. 
Alternatively, excessive stress during depressive episodes could have damaging 
effects on the brain. The association between white matter (WM) volumes and 
depression has been studied less extensively and has resulted in inconsistent 
findings.10-12 
Like depression, hypertension is also an established risk factor for brain 
abnormalities such as WM lesions and decreased GM volumes in prefrontal-
limbic areas.13-18 In addition to damaging effects of hypertension on the brain, 
it has been proposed that alterations in regional brain volume may predispose 
individuals to develop hypertension and cardiovascular disease, due to reduced 
regulatory control on blood pressure and heart rate during stressful situations.15 
According to this theory, subclinical hypertension would be associated with 
similar alterations in brain structure as found in clinical hypertension and CVD. 
Of interest, GM abnormalities in persons with hypertension are reported in 
structures that correspond to the ‘emotional’ areas implicated in depression, 
i.e. in prefrontal-limbic areas such as the prefrontal cortex, the ACC, and the 
hippocampus.13-17,19,20 In addition to emotion processing, these regions have also 
been found to play a role in regulating autonomic functions, such as heart rate 
and blood pressure.21-25 
There may be several explanations for this overlap in brain abnormalities, 
such as a shared vulnerability for depression and hypertension, in which the same 
brain regions could be involved in multiple (i.e. both emotional and cardiovascular) 
processes. In addition, stress is a shared risk factor for the development of high 
CHAPTER 3
42
blood pressure, CVD, and depression, and could also potentially impact brain 
volumes.26-29 Furthermore, it has been suggested that depression in the absence 
and presence of cardiovascular and metabolic conditions has distinctive subtypes, 
in terms of genetic predisposition,30 time of onset,31 and symptomatology.32 
Possibly, these subtypes may be associated with distinctive brain morphology. 
Alternatively, the vascular depression hypothesis posits that brain structural 
abnormalities, such as WM lesions, as a result of vascular pathology may give rise 
to depressive symptoms.31,33,34
Despite the suggested overlap of brain abnormalities in depression and 
hypertension, volumetric brain differences associated with hypertension and 
depression have never been studied simultaneously. The current study investigated 
whether hypertension and depression share regional volumetric alterations in a 
whole brain voxel-wise comparison, and in specific regions of interest (ROIs): the 
hippocampus, inferior frontal gyrus (IFG) and anterior cingulate cortex (ACC). 
The comorbidity of MDD and hypertension has never been taken into account 
in previous MRI research. As comorbid depression is associated with accelerated 
CVD progression,2 comorbid depression and hypertension may have more 
advanced vascular pathology, potentially leading to more pronounced volumetric 
brain alterations. Alternatively, comorbid depression and hypertension may be a 
vulnerable subgroup characterized by distinctive brain morphology. Therefore, the 
effects of hypertension and MDD may not be independent, but rather interactive. 
Methods 
Participants
For this study we used data from the Netherlands Study of Depression and Anxiety 
(NESDA), a multicenter longitudinal cohort study. This study was approved by 
the ethical review board of each participating center and all of the participants 
signed informed consent before inclusion. The design has been described in 
detail elsewhere.35 Out of 2981 NESDA respondents, 301 native Dutch-speaking 
participants aged between 18-57 years were asked to participate in the NESDA 
neuroimaging study if they met the following inclusion criteria: the DSM-IV 
criteria for a diagnosis of MDD and/or anxiety disorder (panic disorder, social 
anxiety disorder, generalized anxiety disorder) in the past six months, or no life-
time DSM-IV diagnosis (except for life-time alcohol and/or drug dependency or 
abuse) (control group). 
The exclusion criteria were: 1) the presence of axis-I lifetime disorders 
other than MDD or anxiety disorder; 2) use of psychotropic medication other 
than SSRIs or infrequent benzodiazepine use (i.e. equivalent to 2 x 10 mg 
oxazepam; 3 times a week, or use within 48 h prior to scanning); 3) presence of 
major internal and/or neurological disorders  (e.g. type 1 diabetes, CVA/TIA); 
4) systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 120 
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mmHg (because this can affect the brain’s hemodynamics and thereby potentially 
confound functional MRI measurements, which was also part of the NESDA 
neuroimaging scan-protocol); 5) dependency or recent abuse (past year) of alcohol 
and/or drugs; 6) use of beta-blockers that may affect the brain’s hemodynamics 
(Carvedilol, Oxprenolol, Pindolol, Bisoprolol, and Nebivolol); 7) general MRI 
contra-indications. 
In total, 301 participants underwent MRI in one of three participating 
centers, i.e. Leiden University Medical Center (LUMC), Academic Medical 
Center Amsterdam (AMC), and University Medical Center Groningen (UMCG). 
Data from patients with CVD (self-reported diagnosis of coronary disease, cardiac 
arrhythmia, angina, heart failure, or myocardial infarction) was excluded (N=6), 
because in this study we specifically examined hypertension. In addition, data 
from 10 participants was excluded because of poor image quality. Therefore the 
final sample consisted of 285 participants. 
Hypertension
To assess hypertension, systolic and diastolic blood pressure was measured during 
supine rest on the right arm, using an OMRON M4 IntelliSense digital blood 
pressure monitor (HEM-752A, Omron Healthcare, Inc., Bannockburn, Illinois, 
USA). The participants were classified as hypertensive when one of the following 
conditions was met: 1) they reported to have hypertension or to receive medication 
for hypertension, or 2) when the average of two consecutive baseline measures 
(at intervals of at least 1 min) for blood pressure exceeded a systolic value of 
140 mm Hg, or 3) when blood pressure exceeded a diastolic value of 90 mm 
Hg, which are commonly used thresholds for hypertension.36 For interpretation 
purposes, we used hypertension as a categorical measure, as descriptive variables 
and brain volumes can then be compared across groups. Moreover, we were 
specifically interested in a clinically relevant measure, that also included currently 
normotensive participants with treated hypertension. Furthermore, we chose to 
incorporate systolic and diastolic blood pressure in one measure, as these were 
highly correlated in the current sample (r=.75).
Depressive disorder
All participants were interviewed with the Composite International Diagnostic 
Interview (CIDI) version 2.1 to establish the presence of depressive and anxiety 
disorders according to the Diagnostic and Statistical manual of Mental disorders 
fourth edition (DSM-IV),37 administered by trained interviewers. In the current 
study analyses were focused on Major Depressive Disorder (half-year recency), while 
anxiety (Social Anxiety Disorder, Panic Disorder with or without Agoraphobia, 
and/or Generalized Anxiety Disorder; half year recency) was accounted for by 




Information about baseline characteristics was obtained from interviews, clinical 
measurements, and questionnaires. Age, sex, years of education, presence of type 
2 diabetes, and medication use were determined during an interview. Measures 
of weight and length were used to calculate body mass index and Doppler 
measures of blood pressure of the arm and ankle were used to calculate ankle-
brachial index (ABI), a measure of peripheral arterial disease. Metabolic syndrome 
was defined according to the revised guidelines of the National Cholesterol 
Education Program (NCEP) Adult Treatment Panel III (ATP III),38,39 described 
in detail previously.40 In short, metabolic syndrome was defined when 3 of the 
following abnormalities were present: increased waist circumference, (treatment 
for) increased triglycerides, (treatment for) reduced high-density cholesterol, 
increased blood pressure or treatment for hypertension, and (treatment for) 
elevated glucose levels. A questionnaire was used to verify smoking status. The 
severity of depression was assessed by the Inventory of Depressive Symptoms 
(IDS). In addition, the groups with MDD might be characterized by different 
depressive symptom profiles. Therefore, the IDS was divided into two depressive 
symptom dimensions: a mood-cognition subscale and an anxiety-arousal subscale, 
which were identified previously in this sample by principal component analysis 
and confirmatory factor analysis.41 
 
MRI data acquisition
Participants were scanned in Philips 3-Tesla MRI scanners located at each of 
the three participating centers, equipped with either a SENSE-6 or a SENSE-8 
channel head coil. Anatomical images were acquired by using a 3-dimensional 
gradient-echo T1-weighted sequence with the following parameters: 170 slices; 
repetition time = 9 ms; echo time = 3.5 ms; matrix: 256 x 256; voxel size: 1 x 1 x 
1 mm; scan duration = 4.5 min.
Data preprocessing
Imaging data were analyzed with Statistical Parametric Mapping software (SPM 
12), implemented in Matlab 7.8.0.  The images were manually reoriented to the 
anterior commissure and segmented into GM, WM, cerebrospinal fluid, skull, 
and soft tissue outside the brain, using the standard segmentation option in SPM 
12, including the ‘light clean-up’ setting. Diffeomorphic Anatomical Registration 
Through Exponentiated Lie algebra (DARTEL) was used for normalization and 
modulation of the images. DARTEL is a recommended method to increase 
the accuracy of inter-subject alignment by modeling the shape of each brain.42 
First, a DARTEL template was created based on the deformation fields that are 
produced during the segmentation procedure. Next, all individual deformation 
fields were registered to this template. After this, the obtained deformed images 
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were used to generate smoothed, spatially normalized, and Jacobian scaled gray 
and white images in MNI space. To increase the signal to noise ratio, the GM and 
WM images were smoothed using an 8 mm full-width-half-maximum Gaussian 
kernel.
Statistical analyses
Voxel-based morphometry (VBM) analyses were masked to exclusively select true 
positive gray and white matter voxels and to optimize sensitivity, by using the 
Masking toolbox.43 In this study a 2x2 ANOVA analysis was performed to test for 
the main and interaction effects of hypertension and MDD. Scan location, age, 
sex, and the current presence of anxiety disorder were entered as covariates in each 
comparison, as these might confound the findings. Furthermore, we examined 
whether adding selective serotonin/norepinephrine re-uptake inhibitor (SSRI/
SNRI) use as a covariate would change the results, as SSRIs and SNRIs might 
affect brain volumes. 
For effects occurring in our a-priori regions of interest (ROIs, i.e. the anterior 
cingulate cortex (ACC), the inferior frontal gyrus (IFG) and the hippocampus; 
based on previous meta-analyses on volumetric differences in MDD,5-8 a composite 
mask was created using the WFU PickAtlas and encompassed these regions as 
defined by the corresponding automated anatomical labeling (AAL) system 
labels. Volumetric studies in the hypertension literature often analyzed total ROI 
volumes instead of employing voxel-based analyses,13,18,20 which is more common 
for the depression literature. To be able to compare our results to both fields 
we analyzed our ROIs as total volumes as well as voxel-based. For the total ROI-
based analyses, we extracted GM volumes of the individual bilateral ROIs (i.e. 
full spatial extent of the AAL labels) and exported these ROI volumes to SPSS 
20.0 to perform ANCOVA. The VBM ROI analyses were performed in SPM, 
in which multiple comparison correction was restricted to the spatial extent of 
composite mask of the ROIs. Effects occurring outside these ROIs had to meet 
whole-brain correction for multiple comparisons. All VBM results are reported 
at p<.05 FWE cluster-corrected, with the initial voxel threshold at p<.005 and a 
spatial cluster extent threshold of k>50. Non-stationarity correction was applied 
to correct for non-uniformity in image smoothness (http://fmri.wfubmc.edu/
cms/software#NS) in all analyses. 
 VBM analyses were corrected for total gray and white matter volumes (i.e. 
Total Brain Volume (TBV)), by using the global values to proportionally scale the 
original voxel values. In the SPSS ROI analyses, TBV was included as a covariate. 
SPSS was also used to analyze the demographic and clinical data, using ANOVA 
and Chi-square with alpha set at p <.05. 
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Age (SD) 36.5 (9.3) 35.0 (10.1) 41.1 (9.8) 42.6 (9.5) <.001
Female (%) 74 (80%) 82 (74%) 18 (44%) 19 (46%) <.001
Education years (SD) 13.7 (2.9) 12.3 (3.0) 13.2 (3.5) 12.1 (3.1) .003
Scan location (%AMC/LUMC/UMCG) 28/41/30 28/41/31 34/39/27 32/32/37 .92
Handedness (% left-handed) 7 (7.6%) 10  (9.0%) 3 (7.3%) 2 (4.9%) .87
SSRI/SNRI (%) 12 (13%) 39 (35%) 9 (22%) 17 (42%) .001
Current anxiety disorder (%) 46 (50%) 64 (58%) 20 (49%) 23 (56%) .64
Systolic blood pressure (SD) 124 (9) 123 (10) 152 (12) 146 (13) <.001
Diastolic blood pressure (SD) 76 (7) 75 (8) 90 (10) 88 (8) <.001
Self-reported treatment for hypertension (%) - - 12 (29%) 10 (24%) .62
Age at onset depression - 22 (10) - 29 (12) <.001
Age at onset hypertension - - 38 (10) 38 (7) .95
Diabetes (%) 0 (0.0%) 3 (2.7%) 1 (2.4%) 3 (7.3%) .09
Body mass index (SD) 24.0 (4.1) 24.8 (4.2) 25.7 (5.1) 27.4 (5.1) .001
Metabolic syndrome (%) 3 (3.3%) 6 (5.5%) 7 (17.1%) 13 (31.7%) <.001
Ankle-brachial index ≤ 0.9 (%) 1 (1.1%) 4 (3.6%) 2 (5%) 1 (2.5%) .60
Current smoker (%) 23 (25%) 39 (35%) 16 (39%) 17 (42%) .18
Depression severity IDS score (SD) 13.1 (11.7) 29.7 (10.6) 15.5 (13.2) 34.5 (11.3) <.001
  Cognitive-mood factor (SD) 3.8 (4.0) 9.6 (3.1) 4.7 (4.5) 10.3 (3.1) <.001
  Anxiety-arousal factor (SD) 3.3 (2.6) 6.1 (2.0) 3.5 (3.0) 6.4 (2.0) <.001
HT = hypertension; MDD = major depressive disorder; SD = standard deviation; AMC = Amsterdam medical Center; LUMC = 
Leiden University Medical Center; UMCG = University Medical Center Groningen; SSRI/SNRI = selective serotonin/norepinephrine 
re-uptake inhibitors (SSRI/SNRI); IDS = inventory of depressive symptomatology. P-values are based on F-test and chi square.
Results 
The total sample consisted of 285 participants (mean age: 37; SD: 10). The 
baseline characteristics are listed in Table 1 for 4 groups: 1) no hypertension and 
no MDD (N=92); 2) no hypertension and MDD (N=111); 3) hypertension and 
no MDD (N=41); 4) both hypertension and MDD (N=41) (Table 1). Participants 
with hypertension were significantly older and less likely to be female, and had 
a higher BMI than participants without hypertension. Participants with MDD 
had less years of education and were more likely to use SSRIs and SNRIs. 
Furthermore, depressive participants with comorbid hypertension had a later 
age at onset of depression and a more severe depression, but did not differ on 
symptom dimensions compared to depressive participants without hypertension. 
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Hypertensive participants with comorbid depression had a lower average systolic 
blood pressure compared to hypertensive participants without depression.
 
ROI-based analyses
We did not observe main effects for hypertension in the SPSS total ROI volume 
analyses, in which mean volumes of each of the total ROIs were analyzed. There 
was a main effect for MDD, in which persons with MDD had lower total GM in 
the ACC (p=.01). In addition, there was an interaction effect in this region (p=.02) 
(Table 2a and Figure 1).  In order to be able to interpret the effect of MDD in 
Table 2a: SPSS ANOVA results of total ROI volumes for GM; Regions of interest tested: bilateral anterior 
cingulate cortex, inferior frontal gyrus, and hippocampus.
Anterior Cingulate cortex F p
HT- = HT+ 0.008 .93
MDD-  > MDD+ 6.3 .01
HT*MDD 5.5 .02
HT = hypertension; MDD = major depressive disorder. 
Comparisons in the analyses: main effects of HT and MDD and interaction effects of HT*MDD were tested in 1 
model, adjusted for scan location, age, sex, anxiety disorder, and whole brain volume (df:1, 276)
Table 2b: Results for SPM whole brain analyses for gray and white matter volumes; and for small volume 





correctedComparison region k x y z F-peak Z-peak
Whole brain
HT * MDD MCC 2247 9 -31 45 25.1 4.75 .01


































HT * MDD Hippocampus 13 -14 -4 -21 9.29 2.80 .87
FWE-cluster corrected p<.05 at initial threshold p<.005; k>50. GM = gray matter; HT = hypertension;  MDD = 
major depressive disorder; MCC = mid cingulate cortex; IFG = inferior frontal gyrus; ACC = anterior cingulate cortex; k 
= cluster size; MNI-coordinate = coordinates of the voxel showing peak significance in mean MNI-space (defined by 
Montreal Neurological Institute). Comparisons in the analyses: main effects of HT and MDD and interaction effects 
of HT*MDD, adjusted for scan location, sex, age and anxiety. ‘HT * MDD’ = interaction effect; ‘MDD- > MDD+’ = 
lower GM for participants with MDD.
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Figure 2: Whole brain interaction effects of hypertension and MDD in A. the posterior mid cingulate 
cortex (MCC) and B. the cerebellum. Images are presented in neurological convention. Color intensities 
reflect F-values.
Figure 1: Location ROI anterior cingulate cortex and total GM volumes per group (in ml). Post hoc 
stratification analyses on hypertension showed that only MDD with hypertension appeared to be significantly 
associated with reduced GM volume in the ACC (F=7.1; p=.01), but not MDD without hypertension (p=.83). 
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the context of an interaction with hypertension, the effect of MDD was stratified 
on hypertension; MDD with hypertension was significantly associated with lower 
GM volume in the ACC (p=.01), but not MDD without hypertension (p=.83). 
From Figure 1 it can be observed that the comorbid group had the lowest ACC 
volume of all groups. There were no significant findings for the hippocampus 
and IFG total volumes.
VBM results
In contrast to the ROI-based analyses in SPSS, there were no significant effects in 
any of the ROIs in the VBM analyses after family-wise error correction. There was 
a marginal interaction effect in the ACC (Table 2b), in which a similar pattern 
was observed as for the ACC in the ROI based analyses (figures not shown). 
To a lesser extent, this was also the case for the hippocampus (Table 2b). Only 
subthreshold explorations at  p<.005 uncorrected in the ROIs, suggested that 
MDD was associated with lower GM volume in clusters in the IFG and ACC 
(Table 2b). 
Furthermore, whole-brain voxel-based analyses (table 2B) revealed significant 
interaction effects in the posterior mid-cingulate cortex (MCC) (k=2247; F=25.1; 
p
FWE
=.01) and in the cerebellum (k=2138; F=13.6; p
FWE
=.01) (Figure 2 and Table 
2b). Figure 3A shows a similar pattern for the MCC as was found for the ACC, 
in which MDD in the presence, but not in the absence of hypertension shows a 
lower GM volume. Stratifying the effect of MDD on the presence and absence 
of hypertension, confirmed this observation. Namely, MDD in the presence of 
hypertension was associated with significantly less GM volume in clusters located 
in the MCC (p
FWE
=.003; k=3526; T=4.55); there was no effect of depression in the 
Figure 3: Pairwise comparison of voxel-based GM volumes in the posterior mid cingulate cortex (MCC) 
(A) and cerebellum (B). HT = hypertension; MDD = major depressive disorder. **: significantly different in 





=.93), neither a subthreshold effect (cluster level p
uncorr 
>.05). Furthermore, Figure 3A shows that the comorbid group was associated 
with the lowest MCC volume of all groups.
For the cerebellum, a different pattern was observed (Figure 3B); MDD 
in the presence of hypertension seemed to be associated with an increased 
volume in the cerebellum, while MDD in the absence of hypertension seemed 
to be associated with a decreased volume. Stratifying the effect of MDD on the 
presence and absence of hypertension showed only subthreshold effects. MDD 
in the presence of hypertension was associated with subthreshold increased GM 
volume (cluster level p
uncorr
=.05; k=727; T=3.01), and MDD in the absence of 
hypertension was associated with subthreshold decreased GM volume (cluster 
level p
uncorr
=.01; k=1202; T=3.44). Whole-brain voxel-based analyses did not reveal 
significant main effects for hypertension, nor for MDD. 
Furthermore, participants with hypertension were on average 6 years 
older compared to participants without hypertension. In order to exclude the 
possibility of a confounding effect of age, we age-matched the hypertension and 
non-hypertension groups by randomly excluding 60 younger individuals from the 




In this structural imaging study we examined whether hypertension and MDD 
are associated with volumetric differences in overlapping brain areas, and 
whether effects are independent or interactive. There were no independent 
effects for hypertension and MDD for gray and white matter volumes. However, 
we did observe an interaction effect for GM volumes in areas implicated in the 
regulation of emotional and autonomic functions: the ACC and in the posterior 
MCC. This interaction indicated that only depression in the presence, but not 
in the absence of hypertension was associated with lower volumes. Persons with 
comorbid hypertension and MDD had the lowest GM in these areas compared 
to the other groups. Furthermore, an interaction effect for GM volume in the 
cerebellum was observed, which showed the opposite pattern; depression in the 
presence of hypertension was associated with marginally higher volumes, whereas 
depression in the absence of hypertension was associated with marginally lower 
volumes. These findings suggest that MDD is differently associated with brain 
volumes in the presence or absence of hypertension. 
Interaction effects 
The most important finding of this study was the interaction effect of hypertension 
and MDD on GM volumes in the ACC and MCC. Brain volumes in these areas 
DEPRESSION, HYPERTENSION, AND BRAIN VOLUMES
3
51
have previously been associated with hypertension and depression in studies 
examining these conditions separately.5-8,13-18 The ACC and MCC were previously 
found to be involved in a variety of emotional and cognitive processes, but also 
in autonomic functions such as cardiovascular modulation.21-24 Stressor-evoked 
blood pressure reactivity has been associated with lower gray matter volume and 
increased activation in the ACC.25 The ACC is part of the central autonomic 
network (CAN), in which the sympathetic output is under tonic inhibitory 
control.3 Disruption of this inhibitory pathway may result in increased heart rate 
and decreased HRV, as well as hypertension.3 
According to the allostatic load theory,44 prolonged periods of psychosocial 
stress (often occurring in depression) can lead to chronic frontal hypoactivity and 
sympathetic disinhibition, increasing the risk for cardiovascular diseases. In line 
with this, prolonged stress has been associated with damage to brain structures 
including the ACC.26-29 Besides the cardiovascular system, the ACC is also part of 
the emotional and stress networks.45,46 Considering its role in emotion, the ACC 
has been implicated in monitoring of emotional salience (pleasant/averseness) 
and initiating changes in behavior in reaction to challenging physical and 
cognitive states.22,23 Taken together, findings of previous studies and the current 
findings of the interaction effect of depression and hypertension on cingulate 
cortex volumes, support the hypothesis that abnormalities in these regions may 
be one of the explanatory factors for the comorbidity of cardiovascular problems 
and depression.19 Multimodal neuroimaging, examining structure and function 
concurrently, may give more insight into the mechanisms underlying the previous 
and current findings for the ACC. Although this cross-sectional study precludes 
inferences regarding causality, it may be that the identified brain volumetric 
differences are predisposed to MDD and hypertension, whether or not due to 
prolonged stress exposure. 
Interestingly, the current study also showed an interaction effect of 
hypertension and depression in the cerebellum. The cerebellum is not only 
involved in motor coordination but is also suggested to play a role in cognitive 
and emotional functioning.47 However, the current findings may be spurious, as 
the unexpected pattern of increased volume of the cerebellum that was observed 
for MDD in the presence of hypertension, and decreased volume for MDD 
without hypertension, were no longer statistically significant after adjustment for 
multiple testing. Nevertheless, as the cluster size was substantial, we cannot as yet 
discard this finding.  
Integrating findings with existing theories on depression subtypes
In line with existing theories,30-32 persons with comorbid depression and 
hypertension differed on a number of characteristics with respect to the comparison 
groups. The comorbid group had a higher age of depression onset and a higher 
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severity of depressive symptoms than the group of depressed participants without 
hypertension. This could not explain the GM findings in the cingulate cortex, 
since depression severity was not associated with GM volumes, whereas a higher 
age of depression onset was associated with larger instead of smaller volumes.48 
On the other hand, the comorbid group was associated with a lower average 
systolic blood pressure compared to hypertension without depression, despite 
the observed lower GM volume for this group. Furthermore, metabolic syndrome 
was twice more prevalent in the comorbid group compared to the hypertension 
group without depression. Including metabolic syndrome as an additional 
covariate did not substantially change the results. Nonetheless, GM volumetric 
abnormalities may predispose towards a broader array of cardiovascular and 
metabolic alterations, surpassing hypertension.49 Thus, our findings support the 
idea that the presence of comorbidity between depression and hypertension may 
indicate a vulnerability that can be visualized in specific brain structures.
Another possibility is that persons with comorbid hypertension and MDD 
are more vulnerable to develop regional brain abnormalities than persons with 
either one condition. This might explain why in this young subclinical sample 
associations were only visible in patients with comorbid MDD and hypertension, 
and not (yet) in patients with hypertension or MDD only. In addition, the findings 
are consistent with the vascular depression hypothesis, in which a subtype of 
depression is postulated with specific structural brain alterations in areas of 
emotion regulation, as a result of vascular pathology.31,33 Thus, the current findings 
are in line with several theories, which do not have to be mutually exclusive.
Absence of independent effects
We hypothesized to find lower brain volumes for hypertension and MDD in 
overlapping brain regions. Unexpectedly, the current study found no independent 
effects for either hypertension or MDD. The current sample may differ from 
previous hypertension samples, because participants with systolic blood pressure 
>180 mm Hg and/or diastolic blood pressure >120 mm Hg and participants using 
beta-blockers potentially influencing brain hemodynamics were excluded from 
the current study. Also, the relatively young age (mean age=42) of the participants 
with hypertension in this sample, and the short duration of the self-reported 
hypertension (mean age at onset=38) may be relevant factors, as GM volume 
reductions observed in participants with high blood pressure may aggravate 
with increasing age.13 Nevertheless, in another large study of young individuals 
(mean age=39), high blood pressure was correlated with lower GM volumes in 
the temporal lobe.16 Considering the current tentative findings, future research 
should focus on the nature of volumetric differences in early and prodromal 
stages of disease.
As previous studies on hypertension and MDD independently reported 
lower brain volumes in frontal-limbic brain areas, we selected the hippocampus, 
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ACC and IFG as ROIs. We only observed significant effects of MDD in the 
ACC. Of note, a previous study in the same sample found that depression was 
associated with lower volumes in clusters in the IFG and ACC, compared to 
healthy controls.48 However, in our analyses we used a more stringent threshold, 
patients with anxiety without comorbid MDD were pooled within the control 
group, and anxiety was taken into account by including it as covariate instead of 
analyzing it as an isolated group. Since anxiety was equally distributed across the 
four groups in the present study, it could not influence the interaction findings. 
Nevertheless, in the FWE-uncorrected analyses, MDD was associated with clusters 
of reduced GM volume in the IFG and ACC. 
The current study found no main or interaction effects for depression and 
hypertension for WM volume analyses. So far, the association between WM 
volumes and depression has not been studied extensively and results have been 
inconsistent.10-12 One volumetric MRI study found that blood pressure did not 
correlate with regional WM volumes.14 Furthermore, research on the effect of 
hypertension on WM has focused predominantly on WM lesions and WM 
integrity instead of WM volumes. One study found that after 50 years of age, but 
not before, comorbid hypertension, obesity, and diabetes mellitus were associated 
with significantly larger WM lesion volumes compared to an age matched group 
without these conditions.50
Strengths and limitations
Our findings should be considered in light of the following strengths and 
limitations. The first major strength is that this is the first study that examined 
the neural correlates of hypertension and depression in one sample. Another 
strength of this study is that the size of the sample was  sufficient to test for 
interaction effects of hypertension and MDD. Furthermore, a strength is the use 
of a diagnostic interview to assess depression. A limitation is that blood pressure 
was only measured twice at one visit, which might not indicate chronic high 
blood pressure. Another limitation is that the use of particular types of beta-
blockers, which are commonly used in the treatment of hypertension, was an 
exclusion criterion, making the findings potentially less generalizable to a more 
clinical population. 
Conclusion
In the current study hypertension and MDD were not independently, but only 
interactively associated with altered GM volumes. The results suggest that in a 
relatively young sample, the combination of MDD and hypertension is uniquely 
associated with lower brain volumes in areas implicated in the regulation of 
emotional and autonomic functions. The observed interaction effect implies that 
future volumetric neuroimaging studies in depression should take into account 
the presence of comorbid hypertension. Moreover, further research should be 
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undertaken to replicate these findings in a sample with more advanced vascular 
disease. In addition, longitudinal research is needed to clarify whether comorbid 
vascular disease and MDD may be a subgroup with specific brain abnormalities, 
and/or whether hypertension and MDD reinforce each other’s impact on brain 
volumes.
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